| Literature DB >> 23681121 |
Changhe Fu1, Guangxu Jin, Junfeng Gao, Rui Zhu, Efren Ballesteros-Villagrana, Stephen T C Wong.
Abstract
SUMMARY: Systematic studies of drug repositioning require the integration of multi-level drug data, including basic chemical information (such as SMILES), drug targets, target-related signaling pathways, clinical trial information and Food and Drug Administration (FDA)-approval information, to predict new potential indications of existing drugs. Currently available databases, however, lack query support for multi-level drug information and thus are not designed to support drug repositioning studies. DrugMap Central (DMC), an online tool, is developed to help fill the gap. DMC enables the users to integrate, query, visualize, interrogate, and download multi-level data of known drugs or compounds quickly for drug repositioning studies all within one system. AVAILABILITY: DMC is accessible at http://r2d2drug.org/DMC.aspx. CONTACT: STWong@tmhs.org.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23681121 PMCID: PMC3702253 DOI: 10.1093/bioinformatics/btt279
Source DB: PubMed Journal: Bioinformatics ISSN: 1367-4803 Impact factor: 6.937